» Articles » PMID: 36016614

Growth Hormone Associated with Treatment Efficacy of Immune Checkpoint Inhibitors in Gastric Cancer Patients

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 26
PMID 36016614
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been widely employed to improve the outcome of gastric cancer patients. In the present study, the impact of posttreatment growth hormone (GH) levels on the treatment efficacy of ICIs for advanced gastric cancer (AGC) patients was assessed.

Methods: Seventy-five AGC patients treated with anti-PD-1 antibodies at The Fourth Hospital of Hebei Medical University were involved. We divided AGC patients into two groups as high-GH group and low-GH group based on the GH level. Immunotherapy efficacy was assessed in terms of objective response rate, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) based on the National Comprehensive Cancer Network Guidelines. The enumeration data were compared by test or Fisher's exact test. Survival curves were drawn by the Kaplan-Meier method, and comparisons between the curves were made using the log-rank test. Multivariate survival analysis was performed using a Cox proportional hazards model.

Results: The higher GH levels were associated with a lower DCR of ICIs with a DCR of 30.0% in the high-GH group and 53.3% in the low-GH group ( = 0.046). The subsequent univariate analysis showed that a high GH level was associated with both shorter PFS ( = 0.016) and shorter OS at the borderline statistical level ( = 0.052) in AGC patients treated with ICIs. Cox model analysis also proved that the GH level was an independent risk factor for the outcome of AGC patients (PFS: = 0.013, HR, 2.424, 95% CI, 1.202-4.890; OS: = 0.014, HR, 3.301, 95% CI, 1.279-8.519).

Conclusions: The post-treatment GH level might be a predictor for ICIs treatment in AGC patients.

Citing Articles

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

Poddubskaya E, Suntsova M, Lyadova M, Luppov D, Guryanova A, Lyadov V Front Immunol. 2024; 15:1493877.

PMID: 39723204 PMC: 11669362. DOI: 10.3389/fimmu.2024.1493877.


The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.

Ji Z, Li J, Zhang S, Jia Y, Zhang J, Guo Z Front Immunol. 2024; 15():1480520.

PMID: 39664382 PMC: 11632129. DOI: 10.3389/fimmu.2024.1480520.


Growth hormone and radiation therapy: friend, foe, or both?.

Bahamondes Lorca V, Wu S Endocr Relat Cancer. 2024; 31(3).

PMID: 38174978 PMC: 10848276. DOI: 10.1530/ERC-22-0371.

References
1.
Zhu T, Ling L, Lobie P . Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J Biol Chem. 2002; 277(47):45592-603. DOI: 10.1074/jbc.M201385200. View

2.
Zhang W, Qian P, Zhang X, Zhang M, Wang H, Wu M . Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. J Biol Chem. 2015; 290(22):13812-29. PMC: 4447958. DOI: 10.1074/jbc.M115.653261. View

3.
Wang Y, Liu S, Yang Z, Algazi A, Lomeli S, Wang Y . Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021; 39(10):1375-1387.e6. PMC: 9126729. DOI: 10.1016/j.ccell.2021.07.023. View

4.
Lin Y, Li S, Cao P, Cheng L, Quan M, Jiang S . The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo. J Endocrinol. 2011; 211(3):249-56. DOI: 10.1530/JOE-11-0100. View

5.
Concha-Benavente F, Srivastava R, Trivedi S, Lei Y, Chandran U, Seethala R . Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2015; 76(5):1031-43. PMC: 4775348. DOI: 10.1158/0008-5472.CAN-15-2001. View